Difference between revisions of "Team:Hannover/Reference"
| (9 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
{{Hannover}} | {{Hannover}} | ||
<html> | <html> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
<body> | <body> | ||
| Line 27: | Line 22: | ||
<li><a href="https://2016.igem.org/Team:Hannover/Description">Description</a></li> | <li><a href="https://2016.igem.org/Team:Hannover/Description">Description</a></li> | ||
<li><a href="https://2016.igem.org/Team:Hannover/Design">Design</a></li> | <li><a href="https://2016.igem.org/Team:Hannover/Design">Design</a></li> | ||
| + | <!--li><a href="???">Modelling</a></li--> | ||
<li><a href="https://2016.igem.org/Team:Hannover/Demonstrate">Demonstrate</a></li> | <li><a href="https://2016.igem.org/Team:Hannover/Demonstrate">Demonstrate</a></li> | ||
<li><a href="https://2016.igem.org/Team:Hannover/Proof">Proof</a></li> | <li><a href="https://2016.igem.org/Team:Hannover/Proof">Proof</a></li> | ||
| Line 41: | Line 37: | ||
<div id="collapseSW" class="panel-collapse collapse in"> | <div id="collapseSW" class="panel-collapse collapse in"> | ||
<ul class="list-group"> | <ul class="list-group"> | ||
| − | <li><a href="https://2016.igem.org/Team:Hannover/ | + | <li><a href="https://2016.igem.org/Team:Hannover/Software#description">Description</a></li> |
| − | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:Hannover/Software#phabricator">Phabricator</a></li> |
| − | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:Hannover/Software#cyberprinter">CyberPrinter</a></li> |
| − | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:Hannover/Software#talsetter">Modeling: TALsetter</a></li> |
| − | <li><a href="TODO">Design</a></li> | + | <!--li><a href="TODO">Design</a></li--> |
<!--li>Modelling</li--> | <!--li>Modelling</li--> | ||
</ul> | </ul> | ||
| Line 56: | Line 52: | ||
</div> | </div> | ||
</div> | </div> | ||
| + | </div> | ||
</div> | </div> | ||
| − | |||
</div> | </div> | ||
<div class="col-sm-8 text-left main-content"> | <div class="col-sm-8 text-left main-content"> | ||
<h1>References</h1> | <h1>References</h1> | ||
<ol id="refs"> | <ol id="refs"> | ||
| − | <li>Boch, J. (2011). TALEs of genome targeting. Nature Biotechnology , 29 (2), pp. 135-136.</li> | + | <li id="1">Boch, J. (2011). TALEs of genome targeting. Nature Biotechnology , 29 (2), pp. 135-136.</li> |
| − | <li>Boch, J., | + | <li id="2">Boch, J.,et al. (2009). Breaking the code of DNA binding specificity of TAL-type III effectors. Science (326), pp. 1509-1512.</li> |
| − | <li> | + | <li id="3">Camarero, J. A., Fushman, D., Cowburn, D., and Muir, T. W. (2001). Peptide chemical ligation inside living cells: In vivo generation of a circular protein domain. Bioorganic & Medicinal Chemistry , pp. 2479-2484.</li> |
| − | <li> | + | <li id="4">Evans, T. C., Benner, J., and Xu, M.-Q. (1999). The cyclization and polymerization of bacterially expressed proteins using modified self-splicing inteins. The Journal of Biological Chemistry , 274 (26), pp. 18359-18363.</li> |
| − | <li> | + | <li id="5">Geissler, R.,et al. (2011). Transcriptional activators of human genes with programmable DNA-specificity. PLOS one .</li> |
| − | <li> | + | <li id="6">iGEM Heidelberg. (2014). The Ring of Fire. Retrieved 10 13, 2016, from https://2014.igem.org/Team:Heidelberg/Toolbox/Circularization</li> |
| − | <li> | + | <li id="7">Hirschler, B. (2016, May). Second baby gets Cellectis "designer" cells to clear leukemia. Retrieved 10 13, 2016, from Reuters: http://www.reuters.com/article/us-health-celltherapy-idUSKCN0XX1F7</li> |
| − | <li> | + | <li id="8">Iwai, H., Lingel, A., and Plückthun, A. (2001). Cyclic green fluorescent protein produced in vivo using an artificially split PI-PfuI intein from Pyrococcus furiosus. The Journal of Biological Chemistry , 276 (19), pp. 16548-16554.</li> |
| − | <li> | + | <li id="9">Lonzaric, J., et al. (2016). Locked and proteolysis-based transcription activator-like effector (TALE) regulation. Nucleic Acids Research , 44 (3), pp. 1471-1481.</li> |
| − | <li | + | <li id="10">Miller, J., et al. (2011). A TALE nuclease architecture for efficient genome editing. Nature Biotechnology , 29 (2), pp. 143-148.</li> |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
<li>Muir, T. W. (2003). Semisynthesis of proteins by expressed protein ligation. Annu. Rev. Biochem. (72), pp. 249-289.</li> | <li>Muir, T. W. (2003). Semisynthesis of proteins by expressed protein ligation. Annu. Rev. Biochem. (72), pp. 249-289.</li> | ||
| − | <li>Office, G.-I. P. (2015, September). World first use of gene-edited immune cells to treat ‘incurable’ leukemia. Retrieved 10 13, 2016, from Great Ormond Street Hospital for Children: http://www.gosh.nhs.uk/news/press-releases/2015-press-release-archive/world-first-use-gene-edited-immune-cells-treat-incurable-leukaemia | + | <li id="11">Office, G.-I. P. (2015, September). World first use of gene-edited immune cells to treat ‘incurable’ leukemia. Retrieved 10 13, 2016, from Great Ormond Street Hospital for Children: http://www.gosh.nhs.uk/news/press-releases/2015-press-release-archive/world-first-use-gene-edited-immune-cells-treat-incurable-leukaemia</li> |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | <li> | + | <li id="12">Qasim, W., et al. (2015). First clinical application of TALEN engineered universal CAR19 T cells in B-ALL. Blood , 126 (23), p. 2046.</li> |
| − | <li> | + | <li id="13">Specter, M. (2016, August). How the DNA Revolution Is Changing Us. Retrieved 10 13, 2016, from National Geographic: http://www.nationalgeographic.com/magazine/2016/08/dna-crispr-gene-editing-science-ethics/</li> |
| − | <li> | + | <li id="14">Streubel, J., et al. (2013). TALEs - Proteine mit programmierbarer DNA-Bindespezifität. BIOspektrum , 2013 (4), pp. 370-373.</li> |
| − | <li> | + | <li id="15">Tavassoli, A., and Benkovic, S. J. (2007). Split-intein mediated circular ligation use in the synthesis of cyclic peptide libraries in E. coli. Nature Protocols , 2 (5), pp. 1126-1133.</li> |
| − | <li>Wood, D. W., | + | <li id="16">Wood, D. W., and Camarero, J. A. (2014). Intein applications: from protein purification and labeling to metabolic control methods. The Journal of Biological Chemistry , 289 (21), pp. 14512-14519.</li> |
</ol> | </ol> | ||
</div> | </div> | ||
Latest revision as of 22:46, 19 October 2016
References
- Boch, J. (2011). TALEs of genome targeting. Nature Biotechnology , 29 (2), pp. 135-136.
- Boch, J.,et al. (2009). Breaking the code of DNA binding specificity of TAL-type III effectors. Science (326), pp. 1509-1512.
- Camarero, J. A., Fushman, D., Cowburn, D., and Muir, T. W. (2001). Peptide chemical ligation inside living cells: In vivo generation of a circular protein domain. Bioorganic & Medicinal Chemistry , pp. 2479-2484.
- Evans, T. C., Benner, J., and Xu, M.-Q. (1999). The cyclization and polymerization of bacterially expressed proteins using modified self-splicing inteins. The Journal of Biological Chemistry , 274 (26), pp. 18359-18363.
- Geissler, R.,et al. (2011). Transcriptional activators of human genes with programmable DNA-specificity. PLOS one .
- iGEM Heidelberg. (2014). The Ring of Fire. Retrieved 10 13, 2016, from https://2014.igem.org/Team:Heidelberg/Toolbox/Circularization
- Hirschler, B. (2016, May). Second baby gets Cellectis "designer" cells to clear leukemia. Retrieved 10 13, 2016, from Reuters: http://www.reuters.com/article/us-health-celltherapy-idUSKCN0XX1F7
- Iwai, H., Lingel, A., and Plückthun, A. (2001). Cyclic green fluorescent protein produced in vivo using an artificially split PI-PfuI intein from Pyrococcus furiosus. The Journal of Biological Chemistry , 276 (19), pp. 16548-16554.
- Lonzaric, J., et al. (2016). Locked and proteolysis-based transcription activator-like effector (TALE) regulation. Nucleic Acids Research , 44 (3), pp. 1471-1481.
- Miller, J., et al. (2011). A TALE nuclease architecture for efficient genome editing. Nature Biotechnology , 29 (2), pp. 143-148.
- Muir, T. W. (2003). Semisynthesis of proteins by expressed protein ligation. Annu. Rev. Biochem. (72), pp. 249-289.
- Office, G.-I. P. (2015, September). World first use of gene-edited immune cells to treat ‘incurable’ leukemia. Retrieved 10 13, 2016, from Great Ormond Street Hospital for Children: http://www.gosh.nhs.uk/news/press-releases/2015-press-release-archive/world-first-use-gene-edited-immune-cells-treat-incurable-leukaemia
- Qasim, W., et al. (2015). First clinical application of TALEN engineered universal CAR19 T cells in B-ALL. Blood , 126 (23), p. 2046.
- Specter, M. (2016, August). How the DNA Revolution Is Changing Us. Retrieved 10 13, 2016, from National Geographic: http://www.nationalgeographic.com/magazine/2016/08/dna-crispr-gene-editing-science-ethics/
- Streubel, J., et al. (2013). TALEs - Proteine mit programmierbarer DNA-Bindespezifität. BIOspektrum , 2013 (4), pp. 370-373.
- Tavassoli, A., and Benkovic, S. J. (2007). Split-intein mediated circular ligation use in the synthesis of cyclic peptide libraries in E. coli. Nature Protocols , 2 (5), pp. 1126-1133.
- Wood, D. W., and Camarero, J. A. (2014). Intein applications: from protein purification and labeling to metabolic control methods. The Journal of Biological Chemistry , 289 (21), pp. 14512-14519.
